All In Biotech

Drug Trial Radar · NCT06644417

Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treated Subjects With Chronic HBV Infection With Low-level Viremia (LLV)

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

122

Actual

Start

Nov 14, 2024

Primary completion

Aug 25, 2025

Study completion Dec 10, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase II multicenter, randomized, double-blind, placebo controlled study designed to evaluate the efficacy and safety in LLV subjects and demonstrate that TQA3605 tablets combined with oral NAs drugs can improve the efficacy and safety of LLV subjects compared with oral NAs drug.

Conditions

  • HBV Infection With LLV

Interventions

  • TQA3605 tablets plus NAsDrug

    TQA3605 tablets is core protein regulator

  • TQA3605 Placebo plus NAsDrug

    Placebo without drug substance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBV DNA (Hepatitis B virus Deoxyribonucleic Acid)Time frame: 24 weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Youan Hospital, Capital Medical Universitybeijing Institute of Hepatology

    Beijing, Beijing Municipality, China

  • Meng Chao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • Zunyi Medical University Affiliated Hospital

    Zunyi, Guizhou, China

  • Zhengzhou No.6 peoples Hospital

    Zhengzhou, Henan, China

  • The Second XIANGYA Hospital Of Central South University

    Changsha, Hunan, China

  • Yueyang Central Hospital

    Yueyang, Hunan, China

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

  • The Fifth People's Hospital of Suzhou

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The sixth people's Hospital Of Shenyang

    Shenyang, Liaoning, China

  • Shandong Public Health Clinical Center

    Jinan, Shandong, China

  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Shanghai Tongren Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi’an, Shanxi, China

  • The First Affiliated Hospital Zhejiang University School Of Medicine

    Hangzhou, Zhejiang, China

  • Lishui People's Hospital

    Lishui, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.